NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
This study will combine three drugs: sorafenib, cyclophosphamide and topotecan.
Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this
combination. The investigators first need to find out the highest dose of sorafenib that can
be given safely together with cyclophosphamide and topotecan. This is the first study to
test giving these three drugs together and will help determine the highest dose of sorafenib
that can safely be given together with cyclophosphamide and topotecan to patients with
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society